Ⅲa（N2）期非小细胞肺癌治疗进展

doi:10.16689/j.cnki.cn11-9349/r.2019.02.019

摘要
图/表
参考文献
相关文章 (0)

全文: PDF (946 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要 Ⅲa(N2)期NSCLC患者存在明显的生存差异，治疗方式的选择存在争论，是需要多学科综合治疗的异质性群体。手术从最重要的治疗方式演变为主要治疗方式之一，未来的地位可能进一步弱化；放疗随着技术层面的进步，将扮演更加重要的角色；化疗与免疫治疗的结合应得到更多的重视，需进一步阐明机理；靶向治疗与免疫检查点抑制剂在该类型患者中的应用值得进一步的研究。肿瘤细胞和宿主免疫系统在免疫微环境中通过相互作用促进免疫逃避并导致肿瘤的复发及转移，目前通过PD途径抗肿瘤等免疫治疗产品已经应用于临床并取得一定成效，该治疗原理主要依赖于浸润到肿瘤和肿瘤微环境中的效应T细胞的功能。根据肿瘤细胞周围免疫细胞（主要为T细胞等）浸润情况，相关研究确立了新型免疫表型分类，为患者治疗和预后提供思路及方向，免疫微环境值得进一步探讨。免疫治疗成为继手术、放化疗等传统治疗方法后一种新的重要治疗手段，为抗肿瘤治疗带来了巨大希望。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ： Ⅲa（N2）期非小细胞肺癌, 治疗方式, 治疗进展, 免疫微环境

Abstract：There is a significant difference in survival between IIIa (N2) stage NSCLC， and the choice of treatment methods is controversial. It is a heterogeneous group that requires multidisciplinary treatment. Surgery has evolved from the most important treatment to one of the main treatments. The future status may be further weakened； radiotherapy will play a more important role as the technical level progresses； the combination of chemotherapy and immunotherapy should receive more attention. The mechanism needs to be further elucidated； the application of targeted therapy and immunological checkpoint inhibitors in this type of patient deserves further study. Interaction between tumor cells and the host immune system in tumor immune microenvironment， through mutual role in the immune microenvironment immune escape and cause the recurrence and metastasis of tumors， the current through PD way antitumor immune therapy such as products have been applied to clinical and obtained certain achievements， the treatment principle mainly relies on the infiltrating into the tumors and the tumor microenvironment effect the function of T cells. According to the infiltration of immune cells around tumor cells (mainly T cells， etc.)， relevant studies have established the classification of new immunophenotypes， providing ideas and directions for the treatment and prognosis of patients， and the immune microenvironment is worth further discussion. Immunotherapy has become a new important treatment method after the traditional treatment methods such as surgery， radiotherapy and chemotherapy.

Key words： Stage IIIa(N2) non-small cell lung cancer Treatment method Progress of treatment Immune microenvironment

基金资助:2018年四川省卫健委课题（18PJ194）

通讯作者: 杨鹤玲，电子邮箱：820588151@qq.com

引用本文:

杨鹤玲蒋鸥，2刘宇，何玉，马成，黄燕，孟凡智. Ⅲa（N2）期非小细胞肺癌治疗进展[J]. 肿瘤代谢与营养电子杂志, 2019, 6(2): 256-260.
YANG He-ling， JIANG Ou， LIU Yu， HE Yu， MA Cheng， HUANG Yan， MENG Fan-zhi. Progress in the treatment of stage IIIa (N2) non-small cell lung cancer. Electron J Metab Nutr Cancer, 2019, 6(2): 256-260.

1.Kim AW， Liptay MJ， Bonomi P， et al. Neoadjuvant chemoradiation for clinically advanced non-small cell lung cancer: an analysis of 233 patients. Ann Thorac Surg. 2011；92(1):241-243.
2.章卫华，叶敏，周荣伟，等. 完整切除ⅢA期非小细胞肺癌术后脑转移的临床特征及危险因素分析. 中国老年学. 2014；34(1):107-108.
3.Robinson LA， Jr HW， Ruckdeschel JC. Treatment of stage IIIA non-small cell lung cancer. Chest. 2003；123(1):188S-201S.
4.Arriagada R， Bergman B， Dunant A， et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004；350(4):351-360.
5.Winton T， Livingston R， Johnson D， et al.Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005；352(25):2589-2597.
6.李桂香，赵达，张庆原，等. ⅢA期非小细胞肺癌立体定向同期放、化疗与手术后化疗的疗效分析. 兰州大学学报(医学版). 2010；36(3):33-36.
7.Douillard JY， Rosell R， De LM， et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association ［ANITA］):a randomised controlled trial. Lancet Oncol. 2006；7(9):719-727.
8.Bonomi M， Pilotto S， Milella M， et al. Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res. 2011；30(1):1-9.
9.Corso CD， Rutter CE， Wilson LD， et al. Re-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the national cancer database. J Thorac Oncol. 2015；10(1):148-155.
10.Mikell JL， Gillespie TW， Hall WA， et al. Post-operative radiotherapy (PORT) is associated with better survival in non-small cell lung cancer with involved N2 lymph nodes: results of an analysis of the national cancer data Base. J Thorac Oncol. 2014；90(5):462-471.
11.Wei-Min M， Tao L， Xiao-Ling X， et al. Adjuvant chemotherapy plus radiotherapy is superior to chemotherapy following surgical treatment of stage IIIA N2 non-small-cell lung cancer. Onco Targets Ther. 2016；9(Issue 1):921-928.
12.刘翼，阿迪力，陆艳荣，等. ⅢA(N2)期非小细胞肺癌术后放疗疗效分析. 中国癌症杂志. 2013；23(6):452-456.
13.Zou B， Xu Y， Li T， et al. A multicenter retrospective analysis of survival outcome following postoperative chemoradiotherapy in non-small-cell lung cancer patients with n2 nodal disease. Int J Radiat Oncol Biol Phys. 2010；77(2):321-328.
14.Rowell NP. Postoperative radiotherapy in non-small-cell lung cancer. Lancet. 1998；352(9137):1384； author reply 1385.
15.Kepka L， Bujko K， Orlowski TM， et al. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy. Radiother Oncol. 2011；98(2):238-243.
16.Lin Y， Liao Z， Komaki R， et al. Evaluation of conventional radiotherapy vs. conformal radiotherapy in the treatment of non-small-cell lung cancer after surgical resection. Chinese-German J Clin Oncol. 2007；6(6):514-518.
17.Bradley JD， Paulus R， Komaki R， et al. A randomized phase III comparison of standard-dose (60Gy) versus high-dose (74Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: results on radiation dose in RTOG 0617. Clin Adv Hematol Oncol. 2014；12(1 Suppl 1):2-4.
18.Spoelstra FOB， Senan S， Péchoux CL， et al. Variations in target volume definition for postoperative radiotherapy in stage III non-small-cell lung cancer: analysis of an international contouring study. Int J Radiat Oncol Biol Phys. 2010；76(4):1106-1113.
19.王冬青，李宝生，陈进琥，等. PET/CT融合图像对Ⅲ期非小细胞肺癌精确放疗靶区和计划的影响. 中华临床医师杂志:电子版. 2011；5(2):353-358.
20.Hounsell A， Hanna GG， Carson KJ， et al. The impact on PTVs and normal lung dose of using 18 F-FDF PET/CT simulation on an already PET/CT staged cohort of NSCLC patients. Inter J Rad Oncol Biol Physics. 2010；78(3):S523-S524.
21.Sorensen JB.Customising chemotherapy in advanced nonsmall cell lung cancer: daily practice and perspectives. Eur Respir Rev. 2011； 20(119):45-52.
22.祁彦君. ⅢA-N2期非小细胞肺癌术前新辅助放化疗临床分析. 数理医药学杂志. 2016；29(10):1473-1474.
23.王思愚，曾智帆，区伟，等. 不可切除ⅢA(N2)期非小细胞肺癌的术前化疗. 中华肿瘤杂志. 2005；27(12):747-749.
24.石鹏飞，张晓明. MVP方案新辅助化疗治疗ⅢA期非小细胞肺癌的疗效观察. 实用癌症杂志. 2016；31(5):769-771.
25.Cerfolio RJ， Bryant AS， Jones VL， et al. Pulmonary resection after concurrent chemotherapy and high dose (60Gy) radiation for non-small cell lung cancer is safe and may provide increased survival. Eur J Cardiothorac Surg. 2009；35(4):718-723.
26.Oxnard GR， Lo PC， Nishino M， et al. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.J Thorac Oncol. 2013；8(2):179-184.
27.Marianne D. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res. 2014；6:63-75.
28.杨海堂，姚烽，赵洋，等. 84例ⅢA-N2期非小细胞肺癌术前新辅助临床治疗结果分析. 中国肿瘤临床. 2015；42(12):620-625.
29.Koshy M. Improved survival associated with neoadjuvant chemoradi-ation in patients with clinical stage IIIA (N2) non-small-cell lung cancer. J Thorac Oncol. 2013；8(7):915-922.
30.韩斌，李川，葛楠，等. ⅢA期非小细胞肺癌术前靶向治疗对手术效果影响. 齐鲁医学杂志. 2017； (3):274-275.
31.贾素文，孙文洲，李晓丽，等. 恶性肿瘤的区域性联合生物治疗的疗效观察. 实用肿瘤学杂志. 2001；15(3):210-211.
32.李向楠. Ⅲa期NSCLC患者术后生物治疗联合化疗与传统化疗的疗效比较. 中国老年学杂志. 2012；32(11):2379-2380.
33.Gubin MM， Zhang X， Schuster H， et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature. 2014；515(7528):577-581.
34.Bindea G， Mlecnik B， Tosolini M， et al.Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013；39(4):782-795.
35.Chen DS， Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017； 541(7637):321-330.
36.Fridman WH， Zitvogel L， Sautès-Fridman， et al. The immune con-texture in cancer prognosis and treatment. Nat Rev Clin Oncol.2017；14(12):717-734.